GentiBio
Andrew is a Principal Development Associate Scientist at GentiBio. Prior to joining GentiBio, Andrew performed infectious disease research and ran laboratory operations for a team exploring B cell responses to vaccination and infection. He has a BS in Genetics and Cellular Biology from Washington State University. When not in the lab, Andrew and his wife are either traveling the globe or planning their next international adventure.
This person is not in the org chart
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.